Published on November 2020 | COVID19 Hydroxychloroquine Remdesivir

Hydroxychloroquine or Remdesivir to Treat COVID-19 Patients

In a multinational study, the use of HCQ or Chloroquine with or without macrolides for the treatment of COVID-19 was discussed. The center records data from 671 hospitals on six continents. Mortality in hospitals and the occurrence of ventricular arrhythmias (unstable or stable ventricular tachycardia or ventricular fibrillation) were observed. In this large analysis, the researchers found no benefit of HCQ or chloroquine (when used alone or in combination with macrolides) in hospital outcomes. Each of the chloroquine or HCQ diets alone or in combination with macrolides was associated with a significant increased risk of clinically significant ventricular arrhythmias and an increased risk of in-hospital death with COVID-19.